- Home
- GEN vs NEUP Comparison
GEN vs NEUP Comparison
Compare GEN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GEN
- NEUP
- Stock Information
- Founded
- GEN 1982
- NEUP 1996
- Country
- GEN United States
- NEUP United States
- Employees
- GEN N/A
- NEUP N/A
- Industry
- GEN Computer Software: Prepackaged Software
- NEUP
- Sector
- GEN Technology
- NEUP
- Exchange
- GEN Nasdaq
- NEUP Nasdaq
- Market Cap
- GEN 17.3B
- NEUP 17.4B
- IPO Year
- GEN N/A
- NEUP N/A
- Fundamental
- Price
- GEN $27.05
- NEUP $4.88
- Analyst Decision
- GEN Buy
- NEUP Strong Buy
- Analyst Count
- GEN 4
- NEUP 1
- Target Price
- GEN $29.00
- NEUP $21.00
- AVG Volume (30 Days)
- GEN 3.4M
- NEUP 1.6M
- Earning Date
- GEN 01-30-2025
- NEUP 02-14-2025
- Dividend Yield
- GEN 1.85%
- NEUP N/A
- EPS Growth
- GEN N/A
- NEUP N/A
- EPS
- GEN 1.02
- NEUP N/A
- Revenue
- GEN $3,901,000,000.00
- NEUP $662,715.00
- Revenue This Year
- GEN $3.99
- NEUP N/A
- Revenue Next Year
- GEN $3.43
- NEUP N/A
- P/E Ratio
- GEN $26.54
- NEUP N/A
- Revenue Growth
- GEN 3.12
- NEUP N/A
- 52 Week Low
- GEN $19.58
- NEUP $2.12
- 52 Week High
- GEN $31.72
- NEUP $15.72
- Technical
- Relative Strength Index (RSI)
- GEN 41.91
- NEUP N/A
- Support Level
- GEN $26.88
- NEUP N/A
- Resistance Level
- GEN $28.09
- NEUP N/A
- Average True Range (ATR)
- GEN 0.59
- NEUP 0.00
- MACD
- GEN -0.01
- NEUP 0.00
- Stochastic Oscillator
- GEN 31.82
- NEUP 0.00
About GEN Gen Digital Inc.
Gen is a cybersecurity pure-play that offers security, identity protection, and privacy solutions to individual consumers. The firm's cyber safety offerings, via brands such as Norton, Avast, and LifeLock, have long maintained their positions as some of the most recognizable consumer-focused security and identity-protection products.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.